Biotronik: J&J ran “sham” recall | Legal Roundup

Conor Medsystems

A Johnson & Johnson (NYSE:JNJ) subsidiary allegedly issued a sham recall of its drug-eluting CoStar coronary stent and spiked a distribution deal with Biotronik AG that cost the German medical device giant $100 million, according to a lawsuit filed in New York’s highest court.

The lawsuit against J&J’s Conor Medsystems accuses it of reneging on a supply contract for the CoStar stent, which Conor recalled in 2007 after it fared badly in a clinical comparison with Boston Scientific’s (NYSE:BSX) Taxus DES. But the recall was a sham aimed at eliminating a competitor to J&J’s Cordis Cypher stent in Europe, according to court documents (Johnson & Johnson bought Conor just before the CoStar recall).

"J&J made what it called a ‘business decision’ to pull CoStar from the market and thereby eliminated Biotronik as a stent competitor in Europe," according to the documents. "J&J imposed that business decision on Conor, and then seized on the label ‘recall’ to justify a breach of the agreement."

"They said they’d supply the stents, and they didn’t," added Biotronik attorney Ronald Rauchberg during a hearing before Justice Bernard Fried of the Supreme Court of the State of New York, according to Health Law 360.

"This case begins and should end with the unambiguous terms of the distribution agreement," Conor Medsystems countered, according to the documents, citing a provision of the deal giving it the "exclusive right and obligation to issue recalls … or similar remedial actions" for CoStar.

"Biotronik does not dispute that if Conor had continued to market CoStar, patients using the product could have an increased risk of heart attack and death if not treated, and would also be more likely to incur the inherent risk of heart attack and death if not treated, and would also be more likely to incur the inherent risk of additional medical procedures," according to a legal filing. "Biotronik also alleges that Conor was not truly motivated by concerns for patients in recalling CoStar, or that the CoStar recall was otherwise a ‘sham,’ but, after extensive discovery, it can marshal no evidence to support that claim."

Last month, Cordis announced its plans to exit the coronary stent business by the end of this year.

Lawsuit: J&J spiked oral cancer test to boost Listerine sales

Johnson & Johnson is accused of further chicanery in another lawsuit, this time in the federal courts.

A complaint filed by Oral Cancer Prevention International Inc. alleges that the health care giant deliberately looked to spike sales of an oral cancer test to protect its Listerine mouthwash.

The suit, filed in the U.S. District Court for New Jersey, accuses J&J of inducing OraPharma Inc. to breach a deal to distribute OCPI’s OralCDx Brush Test to dentists "in order to protect sales of its mouthwash, Listerine, which has been linked to oral cancer," according to the complaint.

"The effect of that behavior, based on OraPharma’s projections, is that an estimated 584 cases of otherwise preventable oral cancer in the State of New Jersey and 7,300 such cases throughout the U.S. will occur over the term of the Sales Agreement. The number of deaths that will result from that conduct is unknown," according to the lawsuit.

On the brink of executing the distribution deal, OraPharma (then owned by J&J, which subsequently sold it to Water Street Healthcare Partners), "OCPI was suddenly informed that the Listerine division of J&J, which had just learned of the imminent signing of the agreement with OCPI, had prevailed upon J&J management to direct OraPharma to not execute it,” according to court documents. "Johnson & Johnson never had any intention of allowing OraPharma to sell OralCDx to those dentists most likely to adopt its use in their practices, but only allowed OraPharma to enter into the Sales Agreement as a means to control and suppress sales of OralCDx to those dentists who J&J considered most likely to recommend the use of Listerine mouthwash to their patients, thereby depriving the public of a known cancer prevention product and destroying OCPI’s dental business."

BD ekes out partial win in retractables case

One front of a long-running war pitting Retractable Technologies Inc. (AMEX:RVP) against industry giants like Becton, Dickinson & Co. (NYSE:BDX) and the group purchasing organizations that dominate the hospital supplies market ended with a partial win for BD.

A federal appeals court overturned part of a $5 million patent infringement verdict against BD and its Integra retractable syringe line. The U.S Court of Appeals for the Federal Circuit ruled that BD’s 3ml version of the device doesn’t violate the RTI patents, but upheld a finding that the 1ml version does infringe.

Because BD dropped the smaller syringe, "there is no impact to our customers," BD spokeswoman Liz Ryan Sax told Bloomberg.

Little Elm, Texas-based Retractable sued BD in June 2007, claiming the Becton syringes infringe patents covering its VanishPoint devices. But RTI’s battle began in the early 1990s, when founder Thomas Shaw invented the first retractable syringe after seeing a news program about a doctor who contracted HIV from an accidental needle stick.

Large medical device makers and the GPOs that act as sales liaisons between them and hospitals effectively kept the RTI syringes off the market until the device makers could come up with competing devices, according to a series of lawsuits Shaw and RTI have filed over the years. In fact, the Federal Circuit decision could bolster another RTI lawsuit accusing BD of anti-trust violations, the company told Bloomberg.

"BD used Retractable Technology’s own patented technology to maintain their monopoly in the syringe market," RTI lawyer Roy Hardin told the news service. "If you’re monopolist in a marketplace, there are certain things you can’t do."

RSS From Medical Design & Outsourcing

  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]
  • MasterControl’s CEO talks EQMS software and new partnerships
    MasterControl offers a quality and compliance software that helps device companies speed time to market and improve their bottom lines. Under Jon’s leadership, the company has blossomed into a market leader and has a unique corporate culture that fosters growth, excellence and quality. In this podcast, MasterControl’s CEO, Jon Beckstrand, will discuss electronic quality management […]
  • BIT Group launches white label IVD solutions
    BIT Group has launched a product line of customizable IVD white label instruments. During recent years, BIT has invested capital and resources developing customizable, ready-to-use IVD systems to address a growing demand. “The IVD market is challenging for our clients,” said Marius Balger, CEO at BIT. “OEM’s must adhere to a growing number of evolving IVD […]
  • Toshiba expands line-up of ARM Cortex-M-based microcontrollers
    Toshiba announced that it has enhanced its current “TX Family” of ARM core-based microcontrollers and started to develop three series of microcontrollers, “TXZ0 series,” “TXZ3 series” and “TXZ4 series,” as part of the “TXZTM Family.” The TXZTM Family is a new collection of flash microcontrollers that support low-power consumption and high-speed operation for IoT and M2M […]
  • Parker Hannifin consolidates, layoffs ahead
    Parker Hannifin plans to consolidate a number of internal divisions, close 2 facilities and expand its Mexican operations, according to an internally distributed letter from Andy Ross, Parker’s engineered materials group president. The company has confirmed the letter was authentic, but has not disclosed how many employees will be affected by the new plans or […]
  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]

Leave a Reply